B
Bullisch
Bullisch · 25%BPMC
$182.36
Szenariopreis
$129.460
+0.181 (+0.14%)Zum Schluss
Loading chart…
- Hoch
- 129.550
- Eröffnung
- 129.350
- Volumengewichteter Durchschnittskurs
- 129.44
- Volumen
- 2.98M
- Marktkap.
- 6.80B
- Tief
- 129.300
- Umsatz
- 385.85M
- EV/EBITDA, TTM
- -568.81
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Analystenbewertungen (9)
+0.97% Aufwärtspotenzial
Kaufen
9 Kaufen
0 Halten
0 Verkaufen
Aktuell: 129.46
Tief
129.00
Durchschnitt
130.71
Hoch
135.00
Wells Fargo
Equal Weight
$129
2025-06-18
Wells Fargo
2025-06-18
Kursziel
$129
Equal Weight
Morgan Stanley
Equal Weight
$129
2025-06-05
Morgan Stanley
2025-06-05
Kursziel
$129
Equal Weight
UBS
Neutral
$129
2025-06-05
UBS
2025-06-05
Kursziel
$129
Neutral
Citi
Neutral
$129
2025-06-04
Citi
2025-06-04
Kursziel
$129
Neutral
Citizens JMP
Market Perform
—
2025-06-03
Citizens JMP
2025-06-03
Kursziel
—
Market Perform
Bewertungskennzahlen
Das aktuelle erwartete KGV von Blueprint Medicines Corp (BPMC) beträgt -110.58, verglichen mit dem 5-Jahres-Durchschnitt von -29.69.
Alphio-AI-Kursszenarien für BPMC
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.507-22BenzingaSanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
3.007-20NASDAQ.COMBPMC Quantitative Stock Analysis
4.507-17NASDAQ.COMAfter Hours Most Active for Jul 16, 2025 : SRPT, NVDA, AAPL, BPMC, PFE, QQQ, INTC, CNH, GE, NI, WFC, F
8.507-14Globenewswire$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
9.007-08BenzingaCogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
BPMC FAQ – beantwortet von Alphio AI
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
9 analysts cover BPMC: 9 rate it Buy, 0 Hold and 0 Sell. The average price target is 130.71.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.